Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: A review of the literature

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 1653-1664

  Lizàn, Luis ^a   Comellas, Marta ^a   Paz, Silvia ^a   Poveda, José Luis ^b   Meletiche, Dennis ^c   Polanco, Carlos ^d  

^a Outcomes'10   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c EMD SERONO INC   (United States)

^d MERCK KGAA   (Germany)

Author keywords

Adherence; Costs; Delivery devices; Multiple sclerosis; References; Satisfaction

Indexed keywords

BETA1A INTERFERON; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; EMERGENCY CARE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INFORMATION RETRIEVAL; MEDICAL DEVICE; MEDLINE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT PREFERENCE; PATIENT SATISFACTION; PUBLICATION; RELAPSE; RHEUMATOID ARTHRITIS; SELF REPORT;

EID: 84919384918     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S67253     Document Type: Article

References (49)

1. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–269.
2. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606–616.
3. Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care. 2013;19 (2 Suppl):S15–S20.
4. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2010;9(5):A387–A394.
5. Kingwell E, Marriott JJ, Jetté N, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013;13:128.
6. Alcalde-Cabero E, Almazán-Isla J, García-Merino A, de Sá J, de Pedro-Cuesta J. Incidence of multiple sclerosis among European Economic Area populations, 1985–2009: the framework for monitoring. BMC Neurol. 2013;13:58.
7. Benito-León J. Multiple sclerosis: is prevalence rising and if so why? Neuroepidemiology. 2011;3(3–4):236–237.
8. World Health Organization. Atlas: Multiple Sclerosis Resources in the World 2008. Geneva, Switzerland. World Health Organization; 2008. Available from: http://www.who.int/mental_health/neurology/Atlas_MS_WEB.pdf. Accessed December 18, 2013.
9. Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012;18(2 Suppl):7–15.
10. Markowitz CE. The current landscape and unmet needs in multiple sclerosis. Am J Manag Care. 2010;16(8 Suppl):S211–S218.
11. Bandari DS, Sternaman D, Chan T, Prostko CR, Sapir T. Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis. J Manag Care Pharm. 2012;18(9):1–17.
12. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30(2):89–100.
13. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256(4):568–576.
14. Zajicek J. Diagnosis and disease modifying treatments in multiple sclerosis. Postgrad Med J. 2005;81(959):556–561.
15. Centre for Evidene-Based Medicine [homepage on the Internet]. CEBM. Oxford, UK: Centre for Evidence-Based Medicine; 2014. Available from: http://www.cebm.net/?o=1025. Accessed June 5, 2014.
16. Web of Science [homepage on the Internet]. Web of Science. Philadelphia, PA: Thomson Reuters; 2014. Available from: http://wokinfo.com/. Accessed June 5, 2014.
17. Google Scholar [homepage on the Internet]. Google scholar. Mountain View, CA: Google Inc.; 2014. Available from: http://scholar.google.es/. Accessed June 5, 2014.
18. Lehmann A, Aslani P, Ahmed R, et al. Assessing medication adherence: options to consider. Int J Clin Pharm. 2014;36(1):55–69.
19. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47.
20. Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill M W. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19(1 Suppl A):S24–S40.
21. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938–952.
22. Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol. 2008; 255(2):280–287.
23. Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Pref Adherence. 2010;4:1–9.
24. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28(1):51–61.
25. Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ. 2012;15(3):601–609.
26. Oleen-Burkey MA, Dor A, Castelli-Haley J, Lage MJ. The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate. J Med Econ. 2011; 14(6):739–747.
27. Tan H, Yu J, Tabby D, Devries A, Singer J. Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study. Mult Scler. 2010;16(8):956–963.
28. Szkurhan A, Malik S, Dembek C, Agarwal S, Rajagopalan K, Rashid N. Economic impact of persistence to disease modifying therapies for the treatment of Multiple Sclerosis. Value Health. 2010; 13(7):A250–A480. Abstract.
29. Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39–48.
30. Twork S, Nippert I, Scherer P, Haas J, Pöhlau D, Kugler J. Immuno-modulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Curr Med Res Opin. 2007;23(6):1209–1215.
31. de Seze J, Borgel F, Brudon F. Patient perceptions of multiple sclerosis and its treatment. Patient Prefer Adherence. 2012;6:263–273.
32. Beer K, Müller M, Hew-Winzeler AM, et al. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study. BMC Neurol. 2011;11:144.
33. Verdun di Cantogno E, Russell S, Snow T. Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices. Patient Prefer Adherence. 2011;5:173–180.
34. Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients’ benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol. 2009;256(4):554–562.
35. Swinburn P, Shingler S, Ali S, Perard R, Lloyd A. Preferences of multiple sclerosis patients for attributes of self-injection devices. Value Health. 2012;15:A1–A276. Abstract.
36. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–740.
37. O’Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res. 2003;3(1):17.
38. Lage MJ, Carroll CA, Fairman KA. Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment. J Med Econ. 2013;16(9):1146–1153.
39. Bruce JM, Hancock LM, Arnett P, Lynch S. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med. 2010;33(3):219–227.
40. Stockl KM, Shin JS, Lew HC, et al. Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence. J Manag Care Pharm. 2010;16(8):593–604.
41. Halpern R, Becker L, Igbal SU, Kazis LE, Macarios D, Badamgarav E. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm. 2011;17(1):25–39.
42. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30(1):91–99.
43. Kirchhoff T, Ruof J, Mittendorf T, et al. Cost of illness in rheumatoid arthritis in Germany in 1997–1998 and 2002: cost drivers and cost savings. Rheumatology (Oxford). 2011;50(4):756–761.
44. Umar N, Schaarschmidt M, Schmieder A, Peitsch WK, Schöllgen I, Terris DD. Matching physicians’ treatment recommendations to patients’ treatment preferences is associated with improvement in treatment satisfaction. J Eur Acad Dermatol Venereol. 2013;27(6):763–770.
45. Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opin Drug Deliv. 2009;6(9):995–1002.
46. Palumbo A, De La Fuente P, Rodríguez M, et al. Willingness to pay and conjoint analysis to determine women’s preferences for ovarian stimulating hormones in the treatment of infertility in Spain. Hum Reprod. 2011;26(7):1790–1798.
47. Syed M, Rog D, Parkes L, Shepherd GL. Patient expectations and experiences of multiple sclerosis interferon β-1a treatment: a longitudinal, observational study in routine UK clinical practice. Patient Prefer Adherence. 2014;8:247–255.
48. Donovan KA, Greene PG, Shuster JL, Partridge EE, Tucker DC. Treatment preferences in recurrent ovarian cancer. Gynecol Oncol. 2002; 86(2):200–211.
49. Fried TR, Byers AL, Gallo WT, et al. Prospective study of health status preferences and changes in preferences over time in older adults. Arch Intern Med. 2006;166(8):890–895.